4LL Stock Chart & Stats
€5.42
€0.22(2.78%)
At close: 4:00 PM EDT
€5.42
€0.22(2.78%)
Day’s Range― - ―
52-Week Range€3.71 - €8.57
Previous CloseN/A
Volume161.00
Average Volume (3M)113.00
Market Cap
€1.12B
Enterprise Value€1.23B
Total Cash (Recent Filing)€849.91M
Total Debt (Recent Filing)€1.03B
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Feb 23, 2027EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.86
Shares Outstanding181,684,020
10 Day Avg. Volume165
30 Day Avg. Volume113
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.89
Price to Sales (P/S)0.49
P/FCF Ratio4.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€7.12Price Target Upside31.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.78
Revenue Forecast (FY)€2.15B
Bulls Say, Bears Say
Bulls Say
Cash Generation And Margin ImprovementConsistent positive operating and free cash flow gives Teladoc internal funding capacity even while reported earnings remain negative. Improving EBITDA margins indicate operating efficiency is strengthening, supporting investment in products, debt management, and resilience over the next several quarters.
Integrated Care Scale And ProfitabilityIntegrated Care combines a large covered-member base with modest growth and strong segment profitability. Continued membership scale, chronic-care adoption, and international performance can support recurring customer relationships and provide a durable foundation as other business areas transition.
Broader Platform ExpansionExpanding from software and virtual visits into hospital and health-system clinical services broadens Teladoc’s addressable customer base and use cases. The combination can deepen platform relevance, create cross-selling opportunities, and strengthen the business’s long-term position in hybrid care.
Bears Say
Consolidated Revenue ContractionDeclining consolidated revenue signals that Teladoc’s growth engine remains under pressure despite operational improvements. Sustained top-line contraction can limit economies of scale, reduce reinvestment flexibility, and make it harder for margin gains to translate into durable earnings growth.
Persistent Losses And Refinancing ObligationThe continued forecast for a full-year net loss shows that improved cash generation has not yet produced accounting profitability. The upcoming $1 billion convertible maturity also creates a meaningful capital-allocation obligation that could constrain flexibility and require debt financing or cash repayment.
BetterHelp Cash-Pay And Margin PressureBetterHelp’s cash-pay weakness is reducing revenue while the shift toward insurance carries lower gross margins and requires investment. This mix transition may keep the segment’s profitability subdued, offsetting gains elsewhere and making consolidated improvement dependent on successful insurance scaling.
Teladoc News
4LL FAQ
What was Teladoc’s price range in the past 12 months?
Teladoc lowest stock price was €3.71 and its highest was €8.57 in the past 12 months.
What is Teladoc’s market cap?
Teladoc’s market cap is €1.12B.
When is Teladoc’s upcoming earnings report date?
Teladoc’s upcoming earnings report date is Feb 23, 2027 which is in 116 days.
How were Teladoc’s earnings last quarter?
Teladoc released its earnings results on Oct 28, 2026. The company reported -€0.135 earnings per share for the quarter, beating the consensus estimate of -€0.195 by €0.06.
Is Teladoc overvalued?
According to Wall Street analysts Teladoc’s price is currently Undervalued.
Does Teladoc pay dividends?
Teladoc does not currently pay dividends.
What is Teladoc’s EPS estimate?
Teladoc’s EPS estimate is -0.1.
How many shares outstanding does Teladoc have?
Teladoc has 181,684,020 shares outstanding.
What happened to Teladoc’s price movement after its last earnings report?
Teladoc reported an EPS of -€0.135 in its last earnings report, beating expectations of -€0.195. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Teladoc?
Currently, no hedge funds are holding shares in DE:4LL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teladoc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€7.12 (31.45% Upside)
€7.12 (31.45% Upside)
Blogger Sentiment
Bullish
DE:4LL Sentiment 69%
Sector Average 65%
Sector Average 65%
News Sentiment
Bullish
Bullish news 71%
Bearish news 29%
Bearish news 29%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.70%
12-Months-Change
Fundamentals
Return on Equity
-11.63%
Trailing 12-Months
Asset Growth
-3.59%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Teladoc
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.
4LL Company Deck
4LL Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was positive overall. Management reported a solid third quarter with adjusted EBITDA above guidance, expanding margins, strong cash flow and liquidity, improved leverage, Integrated Care growth, and accelerating BetterHelp insurance traction. These positives outweighed the ongoing BetterHelp cash pay decline, lower total revenue and paying users, margin pressure, and continued uncertainty around the business transition.View all DE:4LL earnings summaries4LL Revenue Breakdown
56.44% Teladoc Health Integrated Care
43.56% BetterHelp
4LL Stock 12 Month Forecast
Average Price Target
€7.12
▲(31.45% Upside)
Technical Analysis
American Well
―
Doximity
―
VSee Health
―
Hinge Health, Inc. Class A
―
Omada Health, Inc.
―